About Vaxxas Vaxxas is a biotechnology company pioneering a needle-free vaccination technology designed to enhance immune response, reduce costs, and improve accessibility. The company recently ...

Brisbane-based ObvioHealth has signed a three-year agreement with clinical-stage biotechnology company Vaxxas to support late-stage trials.

Emerging infectious diseases (including community-, hospital- and bioterrorism-acquired infections), emerging resistance to antimicrobial agents and increased social demand are increasing the volume ...

A wireless microchip implanted beneath the retina improved vision in 81% of patients with advanced age-related macular ...

Older adults experiencing irreversible blindness may now be able to see thanks to a system relying on a wireless retinal implant and high-tech glasses ...

Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...

Geographic atrophy, an advanced form of dry age-related macular degeneration, leaves almost five million people around the ...

Genomics company Illumina (NASDAQ:ILMN) in Q3 CY2025, but sales were flat year on year at $1.08 billion. Its non-GAAP profit of $1.34 per share was 14.7% above analysts’ consensus estimates. Is now ...

According to Nova One Advisor, the global genomics data analysis market size is calculated at USD 7.91 billion in 2025 and is ...

The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street ...

A photovoltaic retinal implant shows promise as a way to improve vision in patients with advanced age-related macular ...